DIM Sartorius Stedim Biotech

EPA · FR · Healthcare · Medical Instruments & Supplies · sartorius.com

205.00EUR-1.54%Mkt Cap: 22.02B $P/E: 69.17Today

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; b…

Industry Peers

Medical Instruments & Supplies

Screen all

ISRG

Intuitive Surgical, Inc. - Common Stock

$140.43BUSDP/E 44.8

EssilorLuxottica Societe anonyme

$71.20BUSDP/E 26.7

BDX

Becton, Dickinson and Company Common Stock

$48.16BUSDP/E 30.5

MDLN

Medline Inc. - Class A common stock

$47.91BUSDP/E 44.5

RMD

ResMed Inc. Common Stock

Alcon Inc. Ordinary Shares

$30.82BUSDP/E 48.7

WST

West Pharmaceutical Services, Inc. Common Stock

$25.69BUSDP/E 46.8

SRT3

Sartorius Aktiengesellschaft

Sartorius Aktiengesellschaft

$15.20BUSDP/E 71.6

SOLV

Solventum Corporation Common Stock

$14.95BUSDP/E 10.7

BAX

Baxter International Inc. Common Stock

$12.14BUSD

COO

The Cooper Companies, Inc. - Common Stock

$10.82BUSDP/E 19.6

AVTR

Avantor, Inc. Common Stock

$10.38BUSD

COO

The Cooper Companies, Inc.

$10.29BUSDP/E 18.6

RGEN

Repligen Corporation - Common Stock

$10.25BUSDP/E 248.9

ALGN

Align Technology, Inc. - Common Stock

$10.21BUSDP/E 25.0

ATR

AptarGroup, Inc. Common Stock

$7.62BUSDP/E 21.6

BLCO

Bausch + Lomb Corporation Common Shares

$6.11BUSD

Key Statistics

Company

Market Cap22.02B USD

Enterprise Value24.32B USD

Revenue (TTM)3.27B USD

Gross Profit1.46B USD

Net Income (TTM)288.70M USD

Revenue/Share30.91 EUR

Last Price205.00 EUR

Fiscal Year EndDec 2025

MR QuarterJun 2026

Employees10.5K

CountryFR

SectorHealthcare

IndustryMedical Instruments & Supplies

ISINFR0013154002

Valuation

P/E (Trailing)69.17

P/E (Forward)34.69

PEG1.50

EV/EBITDA27.41

EV/Revenue7.45

P/S6.74

P/B4.76

EPS (TTM)3.01

EPS (Forward)6.00

52W Range

150.0074% of range224.00

52W High224.00 EUR

52W Low150.00 EUR

Profitability

Gross Margin45.33%

Oper. Margin20.11%

EBITDA Margin27.17%

Profit Margin8.95%

ROE6.49%

ROA3.33%

Growth

Revenue Growth2.80%

Earnings Growth37.10%

Cash Flow & Leverage

Operating CF752.39M USD

CapEx (TTM)427.39M USD

FCF Margin6.74%

FCF Yield1.00%

Net Debt2.39B USD

Net Debt/EBITDA2.69

Balance Sheet

Debt/Equity0.64

Current Ratio1.16

Quick Ratio0.48

Book Value/Sh43.74 EUR

Cash/Share2.11 EUR

Dividends

Fwd Div Rate0.69 EUR

Trail. Div Rate0.69 EUR

Div. Yield0.33%

5Y Avg Yield0.35%

Payout Ratio22.92%

Ex-Div DateMar 31, 2026

Pay Date—

Splits

Last Split6:1

Split DateMay 6, 2016

Analyst Consensus

Rating1.5 (Buy)

Strong BuyBuyHoldSellStr. Sell

Target (Mean)237.29 EUR

Upside (mean)+15.7%

Target Range210.00 EUR – 262.00 EUR

210.00+15.7% to mean262.00

# Analysts14

Ownership

Shares Out.97.29M

Float27.62M

Insiders71.50%

Institutions11.90%

Technical

SMA 50190.19 (+7.8%)

SMA 200181.70 (+12.8%)

Beta1.15

S&P 52W Chg14.58%

Avg Vol (30d)90.03K

Avg Vol (10d)105.41K

Technical Indicators

RSI (14)58.4

MACD6.3064

MACD Signal5.9170

MACD Hist.+0.3893

BB Upper223.00 EUR

BB Middle200.28 EUR

BB Lower177.56 EUR

BB Width22.69%

ATR (14)6.377 EUR

Vol Ratio (20d)1.09x